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set plan quality on high-quality output of the KBP software. 
The validated HN model will be available for use in an 
upcoming clinical release of the KBP software. 
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Purpose/Objective: In this study we investigated the 
implementation of a new class-solution of volumetric 
modulated arc therapy (VMAT) for a three-phase adaptive 18F-
FDG-PET-voxel-based dose-painting-by-numbers (DPBN) dose-
escalation treatment. VMAT dose distributions were 
compared to the ones made using a standard 6-beam static 
intensity modulated radiotherapy (sIMRT) technique.  
Materials and Methods: 10 non-metastatic head-and neck 
cancer patients, enrolled in the adaptive arm of a phase II 
DPBN trial were planned both with sIMRT and VMAT. Separate 
treatment plans based on two pre and per-treatment (after 
the 8th fraction) 18F-FDG-PET/CTs and one per-treatment CT 
(after the 18th fraction) were made according to the trial 
protocol (Table 1). Dose distributions were summed on the 
pretreatment CT. Plans were evaluated in terms of dose 
levels, dose painting quality factors (QFs), treatment time 
and verified with Delta4 (Scandidos, Uppsala, Sweden) 
measurements.  
Table 1. Prescribed fraction dose for the three phase 
adaptive treatment protocol. The treatment plans for the 
first 2 phases were based on the 18F-FDG-PET/CT information, 
while for the third phase only CT data was used. 
Abbreviations: GTV = gross tumor volume; PTVHR = high-risk 
planning target volume (3 mm expansion of the high-risk 
clinical target volume - CTVHR); CTVHR = a three-dimensional 
GTV expansion of 1 cm adjusted to air cavities and 
uninvolved bones. 
 
 
 
Results: VMAT plans allowed the same level of dose 
escalation in the targets, while significantly reducing the 
dose to organs-at-risk (OARs). On average, the percentage of 
the ipsilateral parotid volume receiving at least 27 Gy was 
reduced from 44.0% to 38.8% and its median dose from 22.8 
to 19.5 Gy (p<0.05). Gross tumor volume QFs were 
significantly improved with VMAT. In 17 out of 20 phase I and 
phase II treatment plans, VMAT QF was better (maximum 
improvement 2.1%), while for the rest it was similar to sIMRT. 
Planning time of both techniques was similar and arc 
treatment delivery was 2 to 3 times faster. The Delta 4 
measurements were in very good agreement with the dose 
calculation for both types of plans. 
Conclusions: Biologically-guided volumetric modulated arc 
therapy is able to increase the sparing of OARs compared to 
sIMRT without compromising target doses or treatment 
delivery quality. Thus, it becomes a valuable technique for 
an adaptive treatment strategy, which follows the anatomical 
patient changes through the treatment time. The 
significantly faster VMAT delivery reduces the risk on intra-
fraction movement.  
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Purpose/Objective: Proton range uncertainties jeopardize 
the theoretical advantage of intensity modulated proton 
therapy over photon-based modalities. Depending on the 
heterogeneity level, this range uncertainty can grow up to 
4.6% of the nominal range + 1.2mm with typical analytical 
dose calculation methods (Paganetti 2012, PMB). The 
robustness of treatment plans can be further evaluated by 
simulating possible realizations of uncertainties with 
systematic and random components. Such a strategy may be 
a daunting task for analytical algorithms because 
computation time scales linearly with the number of 
scenarios simulated, which increases strongly if random 
errors are considered. Monte Carlo (MC) simulations offer 
here a double advantage: 1) they reduce the range 
uncertainty down to 2.4% + 1.2 mm; 2) they potentially allow 
simulating random errors with no significant increase in 
computation time. This study employs a fast MC tool, which 
can compute the impact of random errors in a single 
simulation. 
Materials and Methods: MCsquare, the new software created 
for this study, implements optimized algorithms on the Xeon 
Phi coprocessor to accelerate MC computations. MCsquare 
can compute a dose distribution in less than one minute. 
Multiple uncertainty scenarios are created. A 2.5 mm 
systematic setup error is modeled by shifting the CT image in 
all 6 directions of space. Random setup errors are modeled 
by a 1 mm random shift for each particle simulated by the MC 
engine. The uncertainty in the conversion from Hounsfield 
units to stopping powers is taken into account by applying a 
+/- 3% uniform bias to the patient densities. The experiment 
involves a water phantom, considering both a traditional plan 
with a PTV (2.5mm isotropic margin) and a robust plan (3% 
density uncertainty, 2.5 mm systematic setup errors). The 
CTV surrounds a circular organ-at-risk. The random error 
model employed in this study considers a large number of 
sampling, meaning an infinite number of fractions. The 
second experiment aims at determining the minimal number 
of fractions required to ensure the validity of this 
approximation. For this purpose, various sequences of 
fractions are generated, with different random errors. 
Results: The robustness of the treatment plan is easily 
verified by looking at the deviations of the DVH curve with 
respect to the nominal plan (red curve). The robust plan 
shows small deviations compared to the traditional PTV plan. 
Considering only random errors, the DVH distributions no 
longer vary for treatment with more than 30 fractions. This 
result validates the assumption of the infinite random 
sampling for our robustness test for typical fractionation 
strategies. 
